Clinical, Laboratory, and Molecular Aspects of Factor V Deficiency

Abstract

Factor V (FV) is a glycoprotein that plays a pivotal role in hemostasis, being involved in coagulant and anticoagulant pathways. Congenital FV deficiency is a rare bleeding disorder with an incidence of 1 per million live births, considering the most severe homozygous form. FV deficiency is diagnosed using routine coagulation tests and FV activity assays. Several mutations, including missense, nonsense, and frameshift, have been detected in the F5 gene. Clinical symptoms are variable, ranging from mild ecchymoses and mucosal bleeding to life-threatening intracranial hemorrhage. The mainstay of treatment includes fresh-frozen plasma, preferentially virus-inactivated. In this narrative review, we provide an update of the main laboratory, molecular, clinical, and therapeutic features of inherited FV deficiency.

Keywords

factor V deficiency - inherited - bleeding - therapy

Publication History

Article published online:
27 August 2024

• References

• 1 Tabibian S, Shiravand Y, Shams M. et al. A comprehensive overview of coagulation factor V and congenital factor V deficiency. Semin Thromb Hemost 2019; 45 (05) 523-543
• 2 Duga S, Asselta R, Tenchini ML. Coagulation factor V. Int J Biochem Cell Biol 2004; 36 (08) 1393-1399
• 3 De Pablo-Moreno JA, Miguel-Batuecas A, de Sancha M, Liras A. The magic of proteases: from a procoagulant and anticoagulant factor V to an equitable treatment of its inherited deficiency. Int J Mol Sci 2023; 24 (07) 24
• 4 Camire RM. A new look at blood coagulation factor V. Curr Opin Hematol 2011; 18 (05) 338-342
• 5 Dahlbäck B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol 2016; 38 (Suppl. 01) 4-11
• 6 Yang TL, Cui J, Rehumtulla A. et al. The structure and function of murine factor V and its inactivation by protein C. Blood 1998; 91 (12) 4593-4599
• 7 Lippi G, Favaloro EJ, Montagnana M, Manzato F, Guidi GC, Franchini M. Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis 2011; 22 (03) 160-166
• 8 Dahlbäck B. Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short. J Thromb Haemost 2023; 21 (04) 716-727
• 9 Peyvandi F, Favaloro EJ. Rare bleeding disorders. Semin Thromb Hemost 2009; 35 (04) 345-347
• 10 Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost 2009; 35 (04) 382-389
• 11 Owren PA. Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1 (6449) 446-448
• 12 Vos HL. An online database of mutations and polymorphisms in and around the coagulation factor V gene. J Thromb Haemost 2007; 5 (01) 185-188
• 13 Thalji N, Camire RM. Parahemophilia: new insights into factor v deficiency. Semin Thromb Hemost 2013; 39 (06) 607-612
• 14 Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood 1995; 86 (05) 1820-1827
• 15 Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003; 102 (08) 2856-2861
• 16 Dorgalaleh A, Alavi SER, Tabibian S. et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology 2017; 22 (04) 224-230
• 17 Zheng C, Zhang B. Combined deficiency of coagulation factors V and VIII: an update. Semin Thromb Hemost 2013; 39 (06) 613-620
• 18 Spreafico M, Peyvandi F. Combined factor V and factor VIII deficiency. Semin Thromb Hemost 2009; 35 (04) 390-399
• 19 Soff GA. Combined factor V and factor VIII deficiency. Clin Adv Hematol Oncol 2012; 10 (07) 474-476
• 20 Batsuli G, Kouides P. Rare coagulation factor deficiencies (factors VII, X, V, and II). Hematol Oncol Clin North Am 2021; 35 (06) 1181-1196
• 21 Bolton-Maggs PH. The rare inherited coagulation disorders. Pediatr Blood Cancer 2013; 60 (Suppl. 01) S37-S40
• 22 Pogue RE, Cavalcanti DP, Shanker S. et al. Rare genetic diseases: update on diagnosis, treatment and online resources. Drug Discov Today 2018; 23 (01) 187-195
• 23 Yang J, Mao H, Sun L. Congenital coagulation factor V deficiency with intracranial hemorrhage. J Clin Lab Anal 2022; 36 (11) e24705
• 24 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103 (04) 1067-1069
• 25 Ehtisham M, Shafiq MA, Shafique M, Mumtaz H, Shahzad MN. Owren's disease: a rare deficiency. Cureus 2021; 13 (08) e17047
• 26 Ozkaya H, Akcan AB, Aydemir G, Akcan M, Kul M. Factor V deficiency associated with congenital cardiac disorder and intracranial hemorrhage. Indian J Hematol Blood Transfus 2013; 29 (02) 99-101
• 27 Franchini M, Marano G, Pupella S. et al. Rare congenital bleeding disorders. Ann Transl Med 2018; 6 (17) 331
• 28 Chingale A, Eisenhut M, Gadiraju A, Liesner R. A neonatal presentation of factor V deficiency: a case report. BMC Pediatr 2007; 7: 8
• 29 Wei Y, He Y, Guo X. Clinical phenotype and genetic analysis of twins with congenital coagulation factor V deficiency. J Pediatr Hematol Oncol 2022; 44 (02) e482-e486
• 30 Thomassen MC, Castoldi E, Tans G. et al. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool. Haematologica 2003; 88 (10) 1150-1156
• 31 Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem 2004; 279 (04) 2383-2393
• 32 Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995; 270 (35) 20794-20800
• 33 Duckers C, Simioni P, Spiezia L. et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112 (09) 3615-3623
• 34 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339 (04) 245-253
• 35 Franchini M, Mannucci PM. Adjunct agents for bleeding. Curr Opin Hematol 2014; 21 (06) 503-508
• 36 Franchini M, Mannucci PM. The never ending success story of tranexamic acid in acquired bleeding. Haematologica 2020; 105 (05) 1201-1205
• 37 Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med 2017; 6 (04) 45
• 38 Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood 2019; 133 (05) 415-424
• 39 Liumbruno GM, Marano G, Grazzini G, Capuzzo E, Franchini M. Solvent/detergent-treated plasma: a tale of 30 years of experience. Expert Rev Hematol 2015; 8 (03) 367-374
• 40 Marietta M, Franchini M, Bindi ML, Picardi F, Ruggeri M, De Silvestro G. Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document. Blood Transfus 2016; 14 (04) 277-286
• 41 Franchini M, Crestani S, Frattini F, Sissa C, Bonfanti C. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond. Semin Thromb Hemost 2015; 41 (03) 342-347
• 42 Drzymalski DM, Elsayes AH, Ward KR, House M, Manica VS. Platelet transfusion as treatment for factor V deficiency in the parturient: a case report. Transfusion 2019; 59 (07) 2234-2237
• 43 Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001; 7 (Suppl. 01) 16-22
• 44 Simioni P, Novembrino C, Bulato C. et al. In vitro study of a new plasma-derived factor V (FV) concentrate: dose-response evaluation in plasma from patients with congenital FV deficiency. . [abstract] Res Pract Thromb Haemost 2017; 1 (Suppl. 01) 848
• 45 Bulato C, Novembrino C, Anzoletti MB. et al. “In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. Haemophilia 2018; 24 (04) 648-656